Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

TSXV:RX - Post Discussion

Biosyent Inc > Jason Del Vicario- BNN - Buy
View:
Post by Possibleidiot01 on Oct 03, 2022 8:24pm

Jason Del Vicario- BNN - Buy

BUY

BioSyent Inc(RX-X)

02/10/2022 at 08:00pm
 
Small Canadian pharmaceutical company. High cash flow yield. License products to be distributed across Canada. Company has strong financials and low debt. P/E ratio in the mid-teens (undervalued). Iron supplement product is sole source of revenue(risky). Founder led company with 17% ownership.
Consumer Products
 
$7.340
Owned
Comment by retiredcf on Oct 04, 2022 7:03am
Was surprised at yesterday's decline given that it was such a strong day in the market and following these positive comments. It doesn't mean much as trading volume was low and 80% of it came at 2 pm. The final drop from $7.51 to $7.34 was near the close and for only 200 shares.  GLTA
Biosyent Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities